Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo

Journal of Investigative Dermatology

Volumn 131, Issue 2, 2011, Pages 495-503

  Werzowa, Johannes ^a   Koehrer, Stefan ^a   Strommer, Sabine ^a   Cejka, Daniel ^a   Fuereder, Thorsten ^a   Zebedin, Eva ^a   Wacheck, Volker ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME REPRESSION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 78651388423     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.327     Document Type: Article

References (33)

1. Ali K, Camps M, Pearce WP et al. (2008) Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 180:2538-44
2. Bain J, Plater L, Elliott M et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315
3. Banaszynski LA, Liu CW, Wandless TJ (2005) Characterization of the FKBP.rapamycin.FRB ternary complex. J Am Chem Soc 127:4715-21
4. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335-48
5. Chaisuparat R, Hu J, Jham BC et al. (2008) Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Res 68:8361-8
6. Chen XG, Liu F, Song XF et al. (2010) Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways. Mol Carcinog 49:603-10
7. Cheng JQ, Lindsley CW, Cheng GZ et al. (2005) The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24:7482-92
8. Corvera S, Czech MP (1998) Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol 8:442-6
9. Denley A, Kang S, Karst U et al. (2007) Oncogenic signaling of class I PI3K isoforms. Oncogene 27:2561-74
10. Fan QW, Knight ZA, Goldenberg DD et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9:341-9
11. Foukas LC, Claret M, Pearce W et al. (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441:366-70
12. Hay N (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8:179-83
13. Hudes G, Carducci M, Tomczak P et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-81
14. Karbowniczek M, Spittle CS, Morrison T et al. (2007) mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 128:980-7
15. Kharas MG, Janes MR, Scarfone VM et al. (2008) Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 118:3038-50
16. Knight ZA, Gonzalez B, Feldman ME et al. (2006) A Pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733-47
17. Lopez-Fauqued M, Gil R, Grueso J et al. (2009) The dual PI3K/mTOR inhibitor (PI-103) promotes immunosupression, in vivo tumor growth and increases survival of sorafenib treated melanoma cells. Int J Cancer 126:1549-61
18. Margolin K, Longmate J, Baratta T et al. (2005) CCI-779 in metastatic melanoma. Cancer 104:1045-8
19. Marone R, Erhart D, Mertz AC et al. (2009) Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res 7:601-13
20. Meier F, Schittek B, Busch S et al. (2005) The RAS/RAF/MEK/ERK and PI3K/ AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10:2986-3001
21. O'Reilly KE, Rojo F, She QB et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-8
22. Raynaud FI, Eccles SA, Patel S et al. (2009) Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 8:1725-38
23. Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18:77-82
24. Soulard A, Hall MN (2007) SnapShot: mTOR signaling. Cell 129:434
25. Stahl JM, Sharma A, Cheung M et al. (2004) Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64:7002-10
26. Stambolic V, Suzuki A, De la Pompa JL et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39
27. Sutherlin DP, Sampath D, Berry M et al. (2010) Discovery of (thienopyr-imidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J Med Chem 53:1086-97
28. Takeuchi H, Kondo Y, Fujiwara K et al. (2005) Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphati-dylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65:3336-46
29. Thallinger C, Werzowa J, Poeppl W et al. (2007) Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. J Invest Dermatol 127:2411-7
30. Tsao H, Zhang X, Fowlkes K et al. (2000) Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 60:1800-4
31. Werzowa J, Cejka D, Fuereder T et al. (2009) Suppression of mTORC2 dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002. Br J Dermatol 160:955-64
32. Workman P, Clarke PA, Raynaud FI et al. (2010) Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 70:2146-57
33. Wu H, Goel V, Haluska FG (2003) PTEN signaling pathways in melaoma. Oncogene 22:3113-22